1. Known or suspected somatostatin receptor positive tumour including but not limited to GNET, PNET, pulmonary NET, PRUNK NET, pheochromocytoma, paraganglioma, medullary thyroid cancer, and medulloblastoma. Supporting evidence may include MRI, CT, biochemical markers, OctreoscanTM, 18F-FDG PET/CT and/or pathology report from surgery or biopsy;